Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
WuXi AppTec
Pharma
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Akeso and Summit's ivonescimab handily beat Keytruda in a China phase 3 study. The House passed the BIOSECURE Act. Candid emerged with $370 million.
Angus Liu
Sep 13, 2024 8:53am
After BIOSECURE passes in House, targeted companies play defense
Sep 10, 2024 10:40am
BIOSECURE Act heads for possible House vote next week
Sep 5, 2024 3:23pm
Merck, Leqembi, biosecurity—Fierce Pharma Asia
Aug 2, 2024 10:25am
Revenue falls for WuXi AppTec, with BIOSECURE Act on the horizon
Jul 30, 2024 8:49am
House Speaker pledges support for China-targeting BIOSECURE Act
Jul 9, 2024 8:56am
